# Ansa Biotechnologies closes $68M Series A to commercialise enzymatic DNA synthesis

Canonical page: https://technooptimist.io/stories/ansa-biotechnologies-closes-68m-series-a-to-commercialise-enzymatic-dna-93d12f67
Date: 11 Apr 2022
About: [Ansa Biotechnologies](https://technooptimist.io/companies/ansa-biotechnologies.md) · [Enzymatic long-DNA synthesis](https://technooptimist.io/biotech/enzymatic-dna-synthesis.md)
Original source: https://www.biospace.com/article/releases/ansa-biotechnologies-closes-oversubscribed-68-million-series-a-financing-to-power-the-next-era-of-dna-enabled-industries

Ansa raised a $68M Series A led by Northpond Ventures to build high-throughput synthesizers and launch a DNA synthesis service. Its method, first published by the founders in Nature Biotechnology in 2018, tethers each nucleotide to a template-independent polymerase so the enzyme adds exactly one base per cycle. The company argues this avoids the harsh chemistry that limits the length and accuracy of conventional DNA synthesis.

## Key facts

- Brought total private funding to $82M.
- Investors included RA Capital, Mubadala Capital and Horizons Ventures.
- Also working with Microsoft on enzymatic reagents for DNA data storage.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.